Health News Releases

  • Today March 23
March 20, 15:52
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting
Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22,
Samsung Bioepis office in Songdo, Incheon, Republic of Korea
March 18, 16:38
Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates
Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under d
March 18, 15:55
DNA Script Expands Global Access to On-demand DNA Synthesis With Distributor Agreements in Latin America and East Asia
DNA Script, a pioneer in DNA synthesis providing scientists with rapid, on-demand access to high-quality DNA, today announced it has signed distribution agreements with Gencell (https://cts.businesswi
March 17, 16:20
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse
March 17, 16:00
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies
Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics por
SBC Medical Announces Opening of Brand Flagship “NEO Skin Clinic Ginza.”
March 17, 11:30
SBC Medical Announces Opening of Brand Flagship “NEO Skin Clinic Ginza.”
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields,
March 16, 09:23
Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide
Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research collaboration and license agreement with
WHOOP and Samuel Ross MBE Announce First Limited-Edition Collection Drop for PROJECT TERRAIN
March 15, 13:30
WHOOP and Samuel Ross MBE Announce First Limited-Edition Collection Drop for PROJECT TERRAIN
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%3Futm_source%3DPR%26utm_medium%3DPR%26utm_campaign%3DSR_A&esheet=54443959&newsitemid=20260312513358&lan=en-US&anc
March 13, 15:55
C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests to Help Doctors Diagnose Alzheimer’s Disease
C2N Diagnostics, LLC (https://c2n.com/) (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, has reached an agreement with BeauBrain Healthcare (https://beaubra
March 13, 11:40
Andersen Consulting Strengthens Platform with Collaborating Firm Ambit Iberia
Andersen Consulting expands its technology and business transformation capabilities through a Collaboration Agreement with Ambit Iberia, a consulting firm specializing in digital and regulatory soluti
March 12, 16:10
Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets
Veristat (https://www.veristat.com/), a global clinical research organization (CRO) and consultancy specializing in complex studies, announced expanded regulatory and clinical trial services to intern
March 12, 15:55
InterSystems Appoints Former NHS and Mass General Leader Dr. Tim Ferris as Vice President, Healthcare Practice
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced the appointment of Tim Ferris, M.D., as Vice President, Healthcare Practice. T
The Hypervolt 3 line enables users to massage away stress and tension, loosen muscle knots, maintain
March 12, 15:10
Hyperice Introduces Hypervolt 3 Line: More Powerful, Quieter, and Longer-Lasting Percussion Massage Devices
Hyperice (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhyperice.com%2F&esheet=54442271&newsitemid=20260310934508&lan=en-US&anchor=Hyperice&index=1&md5=9dae1327c39b94f4b0ce095f7d63
March 12, 08:36
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site
Chiesi Group (“Chiesi”), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, t
March 11, 15:53
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF
March 11, 15:52
Galderma Completes Successful Placement of EUR 500 Million Eurobond
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Grou
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker
March 11, 15:45
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2Fus%2Fen%2F&esheet=54439889&newsitemid=20260310966566&lan=en-US&anchor=WHOOP&index=1&md5=45c5be6cf83ed6f2f43c9ea
March 11, 08:44
For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025
Ferring today published its 2025 Annual Report (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ferring.com%2Fwp-content%2Fuploads%2Fsites%2F16%2F2026%2F03%2FFerring-Pharmaceutic
March 10, 09:43
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin
Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily
Medical Korea 2026 will take place at Coex, Seoul, from March 19 (Thu) to 22 (Sun), themed on ‘AI-Po
March 06, 16:22
Medical Korea 2026 Spotlights AI-Powered Global Healthcare Transformation and Cross-Border Medical Services
Medical Korea 2026 (https://www.mkconf.org/fairDash.do?hl=ENG), the 16th Global Healthcare & Medical Tourism Conference, will take place March 19-22, 2026, at COEX in Seoul. Hosted by the Ministry
March 05, 16:04
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency, and Core EBITDA of 1.211 billion USD, Growing 18.9% at Constant Currency
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. · Record net sales of 5,207 million USD, surpassing 5 billion
WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform
March 05, 15:40
WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform Globally
WHOOP (https://www.whoop.com/kr/en/), the human performance company, today announced plans to add more than 600 new roles across Software, Research & Design, Hardware, Product, and Marketing as the co
March 05, 09:20
Linnea Achieves CEP Certification for Cannabidiol Isolate
Linnea is proud to announce that its Cannabidiol (CBD) Isolate has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP). The CEP serves to attest that the quality of an act
Swiss Advanced Vision premium IOL lenses for cataract surgery
March 04, 15:50
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance
Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cata
March 04, 11:11
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54436160&newsitemid=20260301580219&lan=en-US&anchor=TSE%3A4502%2FNYSE%
Controller and processor, Filter-less culture bag and reservoir/waste bags *Controller and other acc
March 03, 15:45
PHCbi Launches LiCellGrow™ Cell Expansion System to Support High-Quality and Efficient Production of Cell and Gene Therapies
PHC Corporation’s Biomedical Division (Head Office: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereinafter “PHCbi”), a global provider of laboratory sample storage and cell cultivation solutions
March 03, 14:20
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova
Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data
March 02, 13:30
Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data
Cowellnex Co., Ltd. (Cowellnex)—jointly established by Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and Kyowa Kirin Co., Ltd. (Kyowa Kirin)—and Metagen, Inc. (Metagen), which promotes
March 02, 11:55
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54433496&newsitemid=20260226660598&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md
February 27, 15:39
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results
February 27, 14:30
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acqui
February 25, 15:58
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane prod
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies
February 24, 16:26
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies
Angelini Pharma (https://www.angelinipharma.com/), part of the privately owned Angelini Industries, and Quiver Bioscience (https://www.quiverbioscience.com/) (“Quiver”), a discovery technology and the
February 24, 16:10
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusi
Rare Diseases: Collaboration is key. image: AdobeStock_1308212316
February 24, 10:15
AOP Health on Rare Diseases: Information. Collaboration. Innovation.
Between 27 and 36 million[1] people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment[2]. Progress in diagnosis and treatment is ofte
February 22, 09:40
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency
YolTech Therapeutics (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.yoltx.com%2F&esheet=54428688&newsitemid=20260219197004&lan=en-US&anchor=YolTech+Therapeutics&index=1&md5=5e9
February 20, 09:57
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54427813&newsitemid=20260218745615&lan=en-US&anchor=TSE%3A4
Michael Clay, Caidya's Chief Operating Officer
February 18, 13:05
Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development
Caidya (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.caidya.com%2F&esheet=54426559&newsitemid=20260217431202&lan=en-US&anchor=Caidya&index=1&md5=7b2712d1d79f058b73bc0260a86357
February 18, 09:09
Galderma Announces Appointment of New Chief Financial Officer
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte wi
February 13, 16:00
Angelalign Technology Inc. (6699.HK) Says a Preliminary European Court Ruling on Certain Software Features Will Have Minimal Impact on Users
Angelalign Technology Inc. (6699.HK) (“Angel”) said a ruling by the Unified Patent Court of Düsseldorf, Germany that it preliminarily cease its use of certain software functions that automatically upd
February 12, 15:22
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties
Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Sculptra® across nine diverse patients
February 11, 15:30
Kirin and Immunosens Launch Joint Development of a Self-Testing Service That Uses Urinary IgA to Visualize a Person’s Immune Status
Kirin Holdings Company, Limited (Kirin Holdings) and Immunosens Co., Ltd. (Immunosens) have begun the joint development of a unique “Self-Testing Service[1]” designed to visualize a person’s immune st
February 11, 15:13
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™
Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT based hyaluronic acid injectables ever authorized in J
February 10, 17:30
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54421686&newsitemid=20260210380286&lan=en-US&ancho
February 06, 15:50
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Grou
February 06, 11:40
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading oncol
InterSystems earns four Best in KLAS awards for 2026
February 06, 10:50
InterSystems Honored with Four 2026 Best in KLAS Awards
InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1
February 05, 13:40
China NMPA Approves Promega MSI Detection Kit as Companion Diagnostic for KEYTRUDA®
The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is intended
Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibilit
February 02, 17:16
Aesthetic Brand Lorient Showcases K-Beauty Excellence at IMCAS World Congress 2026
Lorient, a premium aesthetic brand, announced that it has attracted global attention at the 27th IMCAS World Congress 2026 in Paris, garnering over 15,000 professionals and demonstrating its leadershi
February 02, 15:13
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and l
January 30, 15:34
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity
Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course
January 30, 10:50
Organon Completes Divestiture of JADA® System to Laborie
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA®
January 29, 15:52
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54404180&newsitemid=20260128993781&lan=en-US&anc
January 29, 15:24
Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty
Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing de
January 29, 10:40
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G pTau 217 CSF Assay for Research Use Only
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated LUMIPULSE® G immunoassay analyzers. Th
January 26, 16:11
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 20
Concept Medical announces first patient enrollment in the STARS DAPT randomized clinical trial evalu
January 25, 13:30
Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES
Concept Medical Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.conceptmedical.com%2F&esheet=54401002&newsitemid=20260121338054&lan=en-US&anchor=Concept+Medical+Inc.&index=
January 25, 09:30
Parse Biosciences Launches Workflow for Immune Repertoire and Transcriptome Analysis
Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and whole transcriptome analysis
January 23, 09:07
Innovative Research Unveils Potential of Pharmaceutically Processed Mica in Cancer Treatment
A South Korean research team has discovered that pharmaceutically processed mica (PMC), a mineral traditionally used in medicine, may help suppress the growth of non-small cell lung cancer (NSCLC) cel
January 23, 08:30
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the
Life-saving zinc-supplementation and oral rehydration salts kits are proactively distributed to Zamb
January 22, 14:30
International Zinc Association Partners With Pharmanova to Save Children in Zambia
Zinc Saves Kids, a global child‑health initiative of the International Zinc Association (IZA) (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.zinc.org%2F&esheet=54398808&newsite
January 22, 09:16
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership
Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromo
January 21, 15:20
Crown Bioscience San Diego Laboratory Achieves CAP Accreditation, Building on CLIA Certification to Expand Clinical-Grade Capabilities
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced that its San Diego laboratory has achieved College of American Pathologists (CAP) accre
January 21, 13:50
Colgate-Palmolive and WHO Foundation Announce Global Partnership on Oral Health
Today, Colgate-Palmolive announced a new multi-year collaboration with the WHO Foundation to support the World Health Organization’s work on oral health. The four-year funding commitment will help exp
January 21, 11:50
Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas
Parse Biosciences and Graph Therapeutics (Graph) today announced a strategic partnership to create one of the largest and most comprehensive immune cell perturbation atlases. The collaboration will le
January 21, 10:40
WHOOP Becomes Official Health and Fitness Wearable Partner and Team Partner of Scuderia Ferrari HP
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%3Futm_source%3DPR%26utm_medium%3DPR%26utm_campaign%3DSR_A&esheet=54399604&newsitemid=20260119602892&lan=en-US&anc
Jeff Rowe, Syngenta Group CEO
January 19, 17:04
Syngenta to Address Global Agricultural Challenges at WEF, Championing AI to Empower Farmers and Create Open Technology Access
As farmers globally grapple with unprecedented economic, geopolitical, and environmental pressures; the agricultural sector faces a continued contraction. An alarming decrease in active farms worldwid
January 18, 13:45
WEP Clinical Acquires Netherlands-Based CRO Siron Clinical, Expanding Global Phase I-IV Trial Delivery Capabilities
WEP Clinical (WEP) (https://www.wepclinical.com/), a full-service contract research organization (CRO), announces the acquisition of Siron Clinical (Siron) (https://sironclinical.com/), a Netherlands-
January 16, 15:10
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness
Agenus Inc. (https://www.agenusbio.com/) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences
Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC.
January 16, 11:20
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovig
January 15, 15:10
Notice Concerning Change of Representative Executive Officer
H.U. Group Holdings, Inc. (the Company) today announced that it has resolved, at a meeting of the Board of Directors held on January 14, 2026, to change the Company’s Representative Executive Officer
January 15, 10:40
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures wit
Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings
January 15, 10:03
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference
Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. “2026 is a monumental year for us, as we enter into a new chapter for
January 14, 17:05
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas
Agenus Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.agenusbio.com&esheet=54393958&newsitemid=20260112699965&lan=en-US&anchor=Agenus+Inc&index=1&md5=e3584ab25f74ab4a2ec4f1
January 14, 16:32
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January 14-17, 2026. The compan
January 14, 15:20
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54394840&newsitemid=20260113426214&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
January 13, 14:00
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement desig
January 13, 09:02
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic tr
January 11, 10:45
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administra
January 09, 15:00
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
BeOne Medicines Ltd. (https://beonemedicines.com/) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZII
Dr. Anand Tharmaratnam, Novotech CEO and Chairman
January 08, 16:50
Novotech Appoints Anand Tharmaratnam as New CEO
Novotech, a globally recognized full-service biotech clinical research organization (CRO), is pleased to announce the appointment of Dr. Anand Tharmaratnam as its new Chief Executive Officer. Dr. T
January 06, 16:40
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq
Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs,
January 06, 09:12
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform
Clonell Therapeutics, Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.clonell.com%2F&esheet=54386221&newsitemid=20260105515302&lan=en-US&anchor=Clonell+Therapeutics%2C+Inc.&
January 06, 09:04
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54386774&newsitemid=20260101831438&lan=en-US&anchor=TSE%3A4
January 05, 09:06
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order gov
January 05, 08:54
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2,
Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire)
January 02, 17:00
Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11th January 2026
The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare - a leading integrated healthcare provider, has announced the extension of its deadline to January 11, 2026. The a
World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospita
December 31, 2025 14:15
UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy
Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone p
December 23, 2025 09:19
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of
December 23, 2025 09:07
Samsung Bioepis Announces Approval of Ustekinumab Biosimilar in Japan
Samsung Bioepis Co., Ltd. today announced the marketing approval of Ustekinumab BS Subcutaneous Injection 45mg Syringes ‘NIPRO’, a biosimilar referencing Stelara[1] (ustekinumab), developed by Samsung
December 21, 2025 10:30
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platfo
December 19, 2025 16:50
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation
December 18, 2025 17:09
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54379786&newsitemid=20251218728397&lan=en-US&anchor=TSE%3A4
December 18, 2025 15:00
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On
December 18, 2025 11:45
GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners
GE HealthCare (Nasdaq: GEHC) today announced it will supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deli
December 18, 2025 08:53
Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the directors Mr. S
December 17, 2025 15:45
New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observ
Early Phase Oncology Infographic
December 16, 2025 15:30
Novotech Issues White Paper to Help Sponsors Strengthen Early-Phase Oncology Strategy and Execution
Novotech, a leading global full-service clinical research organization (CRO) and scientific advisory company, has released a new white paper, Early-Phase Oncology - Clinical Research Landscape and CRO
December 14, 2025 14:05
Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcomin
Biocytogen Successfully Lists on the STAR Market
December 12, 2025 10:00
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on t
25 per page50 per page75 per page100 per page